



IT-DED<sup>3</sup>


*Recruitment event of IT-DED<sup>3</sup>*



**University of Valladolid**



**Universidad de Valladolid**



**ESR 4**

*Amalia Enríquez-de-Salamanca, PhD*

*Soraya Rojo, PhD*

**ESR 6**

*María J González-García, OD, PhD*

*Yolanda Diebold, PhD*



## Universidad de Valladolid

Founded in 1241 AD

Located in **Valladolid**, (Castilla y León region ) northwestern **Spain**



**ioba**  
Instituto Universitario de  
Oftalmobiología Aplicada

CLINICAL CARE

RESEARCH

TEACHING

**OCULAR SURFACE GROUP**

**High Pressure Processes Group**

Uva Departamento de Ingeniería Química y Tecnología del Medio Ambiente





Headed by Prof M. Calonge (MD, PhD)

## Research lines




- Advanced therapies and nanomedicine
- Biomarkers of inflammation and pain
- Development of new research experimental models

## Target diseases

- **Dry Eye Disease** (Sjögren syndrome, graft vs host disease, Meibomian gland dysfunction...)
- Corneal blindness due to limbal stem cell deficiency
- Chronic ocular pain
- Contact lens discomfort and related pathology
- Other ocular surface inflammatory diseases (allergies, etc)


## Working areas

- Preclinical models: *in vitro*, 3D, *ex-vivo*, *in vivo*
- Clinical studies and trials
  - **controlled environment** (CELab: Controlled Environment laboratory). Vision R&D



IN-VITRO

Human Ocular Surface Epithelial cells



IN-VIVO

Experimental Desiccating DE



Biochemistry and Molecular Biology

*Invest Ophthalmol Vis Sci.* 2015;56:2709-2719.

Quercetin and Resveratrol Decrease the Inflammatory and Oxidative Responses in Human Ocular Surface Epithelial Cells

Antonio Abengózar-Vela,<sup>1,2</sup> Margarita Calonge,<sup>1,2</sup> Michael E. Stern,<sup>3</sup> María Jesús González-García,<sup>1,2</sup> and Amalia Enriquez-De-Salamanca<sup>1,2</sup>

Topical Quercetin And Resveratrol Protect the Ocular Surface In Experimental Dry Eye Disease. Abengózar-Vela A. *Ocular Immunology and Inflammation* Journal. 2018 under review


# OCULAR SURFACE GROUP

## Advanced Therapies and **Nanomedicine** for Ocular Surface Diseases


Nanotechnology for drug delivery




### Preclinical *in vitro* and *ex vivo* testing







Contreras-Ruiz *et al.* Mol Vis. 2011; 17:279–290. IOBA



### Preclinical *in vivo* testing



Enríquez de Salamanca *et al.*  
IOVS. 2006;47(4):1416-25. IOBA





Headed by  
Prof MJ. Cocero


## INTENSIFIED EXTRACTION OF BIOACTIVE COMPOUNDS FROM NATURAL/RENEWABLE RESOURCES

Working on **MW** extraction since 2006:

- ✓ **Polyphenols**: natural sources:  
winery by-products (grape marc and wine lees), aromatic plants
- ✓ Essential oils aromatic plants
- ✓ Lipid and pigments: microalgae



Batch. Lab scale



Continuous. Pilot scale

## FORMULATION OF BIOACTIVE COMPOUNDS

Working on **Formulation** since 2000: carotenoids, **polyphenols**, essential oils

Frequent problem of (bio)active compounds: **Low bioavailability**

- ✓ Degradation with oxygen, light, pH and high temperatures
- ✓ Low permeability
- ✓ Low solubility in water

Reduce  
Particle size

Encapsulation  
with polymers

## ESR-4 project description

*Supervisors:*

*A Enríquez-de-Salamanca (IOBA)*

*S Rojo (HPP)*

### ❖ OBJECTIVE:

To determine the potential **effect** of isolated **natural compounds** on maintenance of **ocular surface health** in inflammatory diseases such as **Dry Eye (DED)**

### ❖ EXPECTED RESULTS:

- ✓ **Extraction and isolation of natural polyphenols:** Olive marc extracts; Isolation of polyphenols: oleuropein, tyrosol, and/or hidroxytyrosol
- ✓ Characterization of **anti-inflammatory** and **antioxidant properties** of natural compounds selected **on ocular surface in vitro** (conjunctival and corneal epithelial cells) and **in vivo** (mouse dry eye model)

## ESR-6 project description

*Supervisors:*

*M J González-García (IOBA)*

*Y Diebold (IOBA)*

### ❖ OBJECTIVE:

To study the **biocompatibility** and **efficacy** of different **drug delivery systems** loaded with **natural compounds** and formulated to achieve adequate delivery to inflamed anterior eye structures

### ❖ EXPECTED RESULTS:

- ✓ **Characterization** of lead natural compound-based **formulations** to **optimize ocular drug delivery**



## ESRs Planned secondments

### ESR 4

1. **Industrial. iBET:** (5 months). Compounds isolation, in vitro characterization of the antioxidant and anti-inflammatory properties.
2. **Academic. UHC:** (3 months). Selected compound/s formulation/s testing in a mouse desiccating stress dry eye model

### ESR 6

1. **Academic. UEF** (2 months). Acquisition of knowledge about biopharmaceutical barriers and drug kinetics
2. **Industrial. HG&Beyond** (4 months). Proof-of-concept of inclusion of natural compounds in a contact lens as drug carrier



## *4. Doctoral school linked to the beneficiary and offering training on transferable skills*

### Doctorate Programme in Visual Sciences

✓ Will provide ESRs with several **competences:**

- Research skills
- Networking and team work
- Career development
- Scientific writing/publishing
- ...



- ✓ Will provide complementary **formative activities**
- Data managing
  - Statistics
  - Management of information
  - Spanish courses (UVa-Language Center)
  - ...



**Thanks for your attention**